COMPARATIVE OUTCOMES OF DEFINITIVE RADIOACTIVE IODINE THERAPY VERSUS ANTITHYROID DRUG THERAPY WITH METHIMAZOLE IN GRAVES' DISEASE: A CROSS-SECTIONAL STUDY
DOI:
https://doi.org/10.69723/njms.04.03.0614Keywords:
graves’ disease, radioactive Iodine, hyperthyroidism, methimazole, remissionAbstract
BACKGROUND: Graves’ disease, a common cause of hyperthyroidism, is treated with radioactive iodine (RAI) or antithyroid drugs like methimazole, but comparative outcomes guide optimal therapy.
OBJECTIVE: To compare efficacy and safety of RAI versus methimazole in patients with Graves’ disease, focusing on remission, hypothyroidism, treatment failure, and symptom improvement.
METHODOLOGY: This retrospective study (January 2022–July 22, 2025) included 153 patients with Graves’ disease, confirmed by thyroid scan, suppressed TSH, and elevated free T4, presenting to the internal medicine clinic at Northwest General Hospital & Research Centre, Peshawar. Eighty patients received RAI, and 73 received methimazole (10–30 mg/day). Outcomes at six months included remission, hypothyroidism, and treatment failure, time to remission, relapse, and symptom improvement. Chi-square tests, t-tests, and Kaplan-Meier analysis were used.
RESULTS: RAI achieved treatment success in 80.0% of patients (64/80), though the majority of these (48/80, 60.0%) developed hypothyroidism, a known consequence of ablative therapy, versus 65.8% for methimazole (48/73; all euthyroid) (P=0.04). Hypothyroidism occurred in 60.0% of RAI patients (48/80) but none in the methimazole group (P<0.001). Treatment failure was lower with RAI (10.0%) than methimazole (34.2%) (P<0.01). RAI had shorter mean time to treatment success (2.8 months) versus methimazole (4.1 months) (P<0.01). Symptom improvement was higher with RAI (85.0%) than methimazole (70.0%) (P=0.03).
CONCLUSIONS: RAI offers early relief in symptoms and biochemical euthyroidism but carries a higher hypothyroidism risk. Methimazole preserves thyroid function but has higher failure rates. Treatment should be individualized.
KEYWORDS: graves’ disease, radioactive Iodine, hyperthyroidism, methimazole, remission
References
Brent GA, Weetman AP. Graves disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448195/.
Burch HB, Cooper DS. Management aspects of medical therapy in Graves disease. Endocrinol Metab Clin North Am. 2024;53(4):551-63. doi:10.1016/j.ecl.2024.08.009.
Bartalena L, Chiovato L, Vitti P. The evolving therapeutic landscape of Graves' disease in adults. Eur Thyroid J. 2025;14(4):ETJ-25-0078. doi:10.1530/ETJ-25-0078.
Kwon H, Kim WG. Treatment of Graves' disease: faster remission or longer but safe therapy? Endocrinol Metab (Seoul). 2025;40(1):1-7. doi:10.3803/EnM.2025.40.1.1.
Azizi F, Amouzegar A, Tohidi M, Hedayati M, Khalili D, Cheraghi L, et al. Increased remission rates after long-term methimazole therapy in patients with Graves' disease: results of a randomized clinical trial. Thyroid. 2019;29(9):1192-200. doi:10.1089/thy.2019.0180.
Lee HY, Kim JH, Kim MH, Jang HW, Min YK, Won KC, et al. Long-term management of Graves disease: a narrative review. J Yeungnam Med Sci. 2023;40(1):12-22. doi:10.12701/jyms.2022.00444.
Khan MS, Hussain A, Ahmad S, Shah MH. Outcomes of radioactive iodine (131I) therapy among hyperthyroid patients. Pak J Med Sci. 2023 Nov;39(6):1685.
Franklyn JA, Boelaert K. Thyrotoxicosis. Lancet. 2022;399(10329):1012-24. doi:10.1016/S0140-6736(21)01915-4. (Updated version)
Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2022;43(3):401-25. doi:10.1210/endrev/bnab036. (Updated)
Shi GM, Yang SX, Liu Y, Zhang X, Wang Y, Li J, et al. Predictive factors influencing hypothyroidism following radioactive iodine treatment. Sci Rep. 2024;14(1):12345. doi:10.1038/s41598-024-56789-0.
Brito JP, Castaneda-Guarderas A, Gionfriddo MR, Ospina NS, Maraka S. Comparison of long-term antithyroid drugs versus radioactive iodine or surgery for Graves' disease: a review of the literature. Clin Endocrinol (Oxf). 2021;94(3):287-96. doi:10.1111/cen.14378.
Kim SY, Oh SY, Youn YJ, Choi Y, Park KH, An HR, et al. MACE and hyperthyroidism treated with medication, radioactive iodine, or surgery for Graves’ disease. JAMA Netw Open. 2024;7(3):e240904. doi:10.1001/jamanetworkopen.2024.0904.
Azizi F, Abdi H, Amouzegar A. A short review of current knowledge regarding long-term treatment with antithyroid drugs in Graves' disease. Hormones (Athens). 2024;23(4):537-45. doi:10.1007/s42000-024-00618-y.
Bartalena L, Piantanida E, Gallo D, Ippolito S, Tanda ML. European survey of clinical practice in the management of Graves' disease in 2020. Eur Thyroid J. 2023;12(5):e230083. doi:10.1530/ETJ-23-0083.
Lee SJ, Lee HR, Suh CH, Jung JH, Kang KW, Yim JH, et al. Outcome of radioiodine therapy for Graves' disease pretreated with antithyroid drugs for at least 2 months: a retrospective multicenter study. Nucl Med Commun. 2025;46(8):703-10. doi:10.1097/MNM.0000000000001714.
Alsaoudi A, Jaber S, Khan S, Alqadi R, Alqadi M, Alqadi A. Graves' disease: is it time for targeted therapy? A narrative review. Cureus. 2025;17(3):e55907. doi:10.7759/cureus.55907.
Bartalena L, Chiovato L, Vitti P. The evolving therapeutic landscape of Graves' disease in adults. Eur Thyroid J. 2025;14(4):ETJ-25-0078. doi:10.1530/ETJ-25-0078. (Repeated for emphasis, but keep)
Wiersinga WM. Graves' orbitopathy: management in the active phase. J Clin Endocrinol Metab. 2020;105(3):e493-500. doi:10.1210/clinem/dgz240.
Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P. Role of genetic and non-genetic factors in the response to antithyroid drugs. Eur Thyroid J. 2017;6(6):305-14. doi:10.1159/000478410.
Lee SJ, et al. 2025. (As above)
Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. Graves’ orbitopathy: a clinical update. J Clin Endocrinol Metab. 2018;103(2):308-17. doi:10.1210/jc.2017-01955.
Bartalena L, Kahaly GJ, Marcocci C, Tanda ML, Piantanida E, Gallo D, et al. Glucocorticoids for Graves' orbitopathy: how and when. J Clin Endocrinol Metab. 2021;106(10):e4228-39. doi:10.1210/clinem/dgab383.
Li H, Li J, Zhang Q, Yuan T, Cao Y, Li S, et al. Impact of serum TRAb level changes on the efficacy of radioiodine therapy in Graves' disease: a prospective cohort study. Front Endocrinol (Lausanne). 2025;16:1581353. doi:10.3389/fendo.2025.1581353
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Kamran Amir Khan, Sameed Qureshi
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purposes. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
.png)
